This partnership seeks to catalyze momentum by pairing emerging biotechnology firms with a network of investors, pharmaceutical executives, and clinical experts. As the pipeline for Alzheimer's treatments grows more complex and targeted, organizers intend to create a high-stakes environment where startups can pitch their development programs to key decision-makers.
In section Releases
CTAD and ADDF Partner to Fast-Track Alzheimer’s Biotech Innovation
The Clinical Trials on Alzheimer's Disease conference and the Alzheimer's Drug Discovery Foundation are joining forces to launch a specialized Biotech Showcase at the 2026 CTAD gathering in Boston. The initiative aims to bridge the gap between scientific discovery and market-ready clinical development for next-generation dementia therapeutics.
ADDF CEO Isobel Coleman noted that the rapid integration of artificial intelligence and a deeper understanding of disease mechanisms have fundamentally altered the landscape compared to five years ago. The showcase will feature three-minute lightning talks and live Q&A sessions, providing entrepreneurs with direct feedback from clinical researchers and immediate access to capital providers. CTAD co-founder Jacques Touchon emphasized that such cross-disciplinary alignment is essential for translating laboratory breakthroughs into personalized patient care. The second submission cycle for companies seeking to participate opens on September 3, 2026, ahead of the main conference scheduled for November 16–19.
Comments (0)
No comments yet. Be the first!